Targeted Nanoparticle Delivery for Ocular Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular diseases such as retinopathies and glaucoma, particularly those involving neovascularization and optic neuropathies, face challenges with side effects and long-term compliance issues due to systemic anti-VEGF therapies, which can lead to off-target effects and reduced efficacy over time.
Innovation Solution
A nanoparticle system comprising a drug core with anti-inflammatory, immune-suppressive, anti-angiogenic, and neuroprotective activities, surrounded by an amphiphilic shell with a targeting ligand that specifically binds to retinal pigment epithelial and optic nerve cells, allowing for targeted delivery and increased intracellular availability and residence time, thereby interfering with VEGF signaling and reducing neovascularization, inflammation, and neurodegeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic anti-VEGF therapy is administered to treat ocular diseases, then the therapeutic effect on neovascularization is improved, but off-target effects on other cell types and systemic side effects occur
Solution Approach 1:
The patent segments the therapeutic approach by using nanoparticles with surface modifications that specifically target ocular tissues. The nanoparticle system divides the drug delivery into targeted segments (ocular) versus non-targeted (systemic), allowing anti-VEGF therapy to act locally on neovascularization while minimizing exposure to other cell types through the use of size-dependent filtration and surface ligand targeting
Solution Approach 2:
The nanoparticle acts as an intermediary carrier that transports anti-VEGF drugs to the ocular target site. This intermediary system allows the drug to reach the intended target (neovascularized ocular tissues) while the nanoparticle's size and surface properties prevent uptake by non-target cells, thus mediating between the drug and the specific target to avoid off-target effects
2Reliability
If continuous anti-VEGF injections are administered, then the therapeutic effect is maintained, but patient compliance deteriorates due to frequent treatments
Solution Approach 1:
The patent applies preliminary action by pre-modifying the drug with nanoparticle carriers that provide sustained release capabilities. This preliminary preparation allows the drug to remain effective over extended periods after a single administration, eliminating the need for frequent injections and improving patient compliance while maintaining therapeutic effect
Solution Approach 2:
The nanoparticle system enables continuity of useful action by providing sustained drug release over time. The controlled release mechanism ensures that therapeutic levels of anti-VEGF agents are maintained continuously in the ocular tissues, replacing the need for repeated discrete injections with a single continuous therapeutic action
3Reliability
If high doses of VEGF neutralizing agents are administered, then the suppression of neovascularization is improved, but damage to RPE cells and photoreceptors increases
Solution Approach 1:
The patent applies local quality by engineering nanoparticles with specific surface properties and sizes that enable selective accumulation in ocular tissues while being excluded from healthy cells. The nanoparticle system creates local high concentration of anti-VEGF agents at the disease site (neovascularized areas) while maintaining low systemic concentrations, thus achieving effective suppression of neovascularization without damaging healthy RPE cells and photoreceptors
Solution Approach 2:
The patent utilizes parameter changes by modifying the physical and chemical parameters of the drug delivery system (nanoparticle size, surface charge, ligand density) to achieve selective targeting. These parameter modifications allow the system to differentiate between diseased and healthy tissues, delivering high doses locally to neovascularized areas while preventing toxic exposure to healthy cells through controlled release and targeted accumulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle system effectively reduces retinal neovascularization, inflammation, and neurodegeneration, with enhanced bioavailability and prolonged action in ocular tissues, improving treatment outcomes for retinopathies and glaucoma while minimizing systemic side effects.
Implementation Method 1
The therapeutic system in accordance with the present invention allows, to transport encapsulated drugs, specifically to retinal pigment epithelial (RPE) cells, endothelial cells, and/or optic nerve cells, after systemic application
Implementation Method 2
thereby interfering with VEGF signaling and reducing neovascularization, inflammation, and neurodegeneration
Data Source
AI summary
The present invention relates to a nanoparticle for use in the treatment of ocular diseases, in particular diseases of the retina (“retinopathies”) or of optic neuropathies, in particular glaucoma.